Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies

Cancer

Volumn 119, Issue 18, 2013, Pages 3377-3384

  Antoun, Sami ^a   Lanoy, Emilie ^a   Iacovelli, Roberto ^a,b   Albiges Sauvin, Laurence ^a   Loriot, Yohann ^a   Merad Taoufik, Mansouriah ^a   Fizazi, Karim ^a   Di Palma, Mario ^a   Baracos, Vickie E ^c   Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

body composition; muscle density; prognosis; renal cell carcinoma; targeted therapy

Indexed keywords

EVEROLIMUS; PLACEBO; SORAFENIB; SUNITINIB; VASCULOTROPIN INHIBITOR;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; BODY COMPOSITION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG TARGETING; FEMALE; HENG RISK SCORE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MUSCLE TISSUE; MUSCULOSKELETAL SYSTEM PARAMETERS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; SCORING SYSTEM; SKELETAL MUSCLE; SKELETAL MUSCLE DENSITY; SURVIVAL TIME;

BODY COMPOSITION; MUSCLE DENSITY; PROGNOSIS; RENAL CELL CARCINOMA; TARGETED THERAPY;

AGED; ANTINEOPLASTIC AGENTS; BODY COMPOSITION; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NEOPLASM METASTASIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84883565044     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28218     Document Type: Article

References (27)

1. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J,. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17: 2530-2540. (Pubitemid 29368255)
2. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27: 5794-5799.
3. Powles T, Hutson TE,. Difficulty in predicting survival in metastatic renal cancer. Lancet Oncol. 2012; 13: 859-860.
4. Jeon HG, Jeong IG, Lee JH, et al. Prognostic value of body mass index in Korean patients with renal cell carcinoma. J Urol. 2010; 183: 448-454.
5. Choi Y, Park B, Jeong BC, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer. 2013; 132: 625-634.
6. Waalkes S, Merseburger AS, Kramer MW, et al. Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer. Cancer Causes Control. 2010; 21: 1905-1910.
7. Donat SM, Salzhauer EW, Mitra N, et al. Impact of body mass index on survival of patients with surgically treated renal cell carcinoma. J Urol. 2006; 175: 46-52. (Pubitemid 41797082)
8. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008; 9: 629-635.
9. Tan BH, Birdsell LA, Martin L, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009; 15: 6973-6979.
10. Kasymjanova G, Correa JA, Kreisman H, et al. Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J Thorac Oncol. 2009; 4: 602-607.
11. Jones LW, Watson D, Herndon JE 2nd, et al. Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer. Cancer. 2010; 116: 4825-4832.
12. Goodpaster BH, Kelley DE, Thaete FL, et al. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol. 2000; 89: 104-110. (Pubitemid 30482569)
13. Sabel MS, Lee J, Cai S, et al. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol. 2011; 18: 3579-3585.
14. Steffens S, Grunwald V, Ringe KI, et al. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? Oncologist. 2011; 16: 1565-1571.
15. Naya Y, Zenbutsu S, Araki K, et al. Influence of visceral obesity on oncologic outcome in patients with renal cell carcinoma. Urol Int. 2010; 85: 30-36.
16. Ladoire S, Bonnetain F, Gauthier M, et al. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist. 2011; 16: 71-81.
17. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134. (Pubitemid 46089673)
18. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010; 116: 4256-4265.
19. Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 4068-4075.
20. Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008; 33: 997-1006.
21. Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol. 2004; 97: 2333-2338. (Pubitemid 39552474)
22. Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010; 21: 1594-1598.
23. Tang PA, Heng DY, Choueiri TK,. Impact of body composition on clinical outcomes in metastatic renal cell cancer. Oncologist. 2011; 16: 1484-1486.
24. Harvey AE, Lashinger LM, Hursting SD,. The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci. 2011; 1229: 45-52.
25. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009; 15: 2920-2926.
26. Cawthon PM, Fox KM, Gandra SR, et al. Do muscle mass, muscle density, strength, and physical function similarly influence risk of hospitalization in older adults? J Am Geriatr Soc. 2009; 57: 1411-1419.
27. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013; 31: 1539-1547.